SRTR Analysis Links Post-Transplant Infection to Worse Survival Across Organ Grafts

Solid organ transplantation depends on a narrow therapeutic balance: enough immunosuppression to prevent rejection, but not so much that immune defense collapses. In a large registry analysis published in Frontiers in Immunology, postoperative infection recorded during follow-up tracked with poorer long-term survival across transplant types, and the association between specific immunosuppressants and infection varied sharply by organ.

The pattern was not uniform. Tacrolimus lined up with lower recorded infection odds after liver and heart transplantation, yet with higher odds after kidney transplantation. Sirolimus moved in the opposite direction of safety in several groups, with higher recorded infection odds after heart, lung, and kidney transplantation. For transplant clinicians, the signal is straightforward: drug class alone does not predict infectious risk well enough without organ context.

Infection Burden Was Highest in Lung and Heart-Lung Recipients

The analysis drew from the Scientific Registry of Transplant Recipients and included 14,814 liver recipients, 48,433 kidney recipients, 38,493 heart recipients, 23,861 lung recipients, 2,484 pancreas recipients, 608 heart-lung recipients, and 7,060 pancreas-kidney recipients. Recorded postoperative infection was common in several groups, but the burden was especially heavy in thoracic transplantation. Lung recipients had infection recorded in 13,634 cases, or 57.14%, and heart-lung recipients in 364 cases, or 59.87%.

By contrast, infection was recorded in 16.48% of liver recipients, 4.31% of kidney recipients, 36.60% of heart recipients, 6.76% of pancreas recipients, and 4.86% of pancreas-kidney recipients. Those differences fit transplant biology. Lung allografts are continuously exposed to the external environment, with ongoing contact to inhaled pathogens and a need for stronger immunosuppression. Liver grafts are generally more tolerogenic, while kidney recipients often sit in a different immunologic and pharmacologic balance, where the same agent can behave differently depending on background regimen and host factors.

Infection Carried a Survival Penalty Across Solid Organ Transplantation

The clearest bedside message from the registry data is the survival penalty attached to infection. Recipients with recorded postoperative infection had higher mortality and lower overall survival across solid organ transplant types. The study used Kaplan-Meier methods, log-rank testing, and Cox regression to examine overall survival, and logistic regression to examine infection status.

This relationship makes biological sense. Infection in the post-transplant period is not an isolated event; it can trigger inflammatory injury, destabilize graft function, increase hospitalization, and interrupt the continuity of immunosuppressive therapy. In a patient with a transplanted organ, any of those steps can tilt the course toward rejection, organ dysfunction, or death. Infection is therefore not only a complication, but a marker of vulnerability that can reconfigure the rest of the clinical course.

Tacrolimus and Sirolimus Did Not Behave the Same Way in Every Organ

Among liver recipients, tacrolimus was associated with lower odds of recorded infection, with an odds ratio of 0.83, 95% CI 0.76 to 0.91, and P < 0.001. In heart transplantation, tacrolimus was also associated with lower odds of infection, with an odds ratio of 0.91, 95% CI 0.87 to 0.95, and P < 0.001. The kidney cohort pointed in the opposite direction: tacrolimus was associated with higher odds of recorded infection, with an odds ratio of 1.58, 95% CI 1.45 to 1.73, and P < 0.001.

Sirolimus showed a different pattern. It was associated with higher odds of recorded infection after heart transplantation, with an odds ratio of 1.23, 95% CI 1.07 to 1.42, and P = 0.00454; after lung transplantation, with an odds ratio of 1.80, 95% CI 1.28 to 2.57, and P < 0.001; and after kidney transplantation, with an odds ratio of 1.41, 95% CI 1.19 to 1.66, and P < 0.001.

These divergences are clinically plausible. Tacrolimus and other calcineurin inhibitors suppress T-cell activation and dampen cytokine signaling, but the net infectious effect depends on the graft, the induction regimen, the steroid burden, comorbidity load, and the center’s prescribing patterns. Sirolimus, as an mTOR inhibitor, affects immune-cell proliferation and can alter wound healing and infection susceptibility in ways that may matter more in organs exposed to higher infectious pressure or more complex postoperative recovery. The same pharmacology does not land identically in a liver recipient and a lung recipient.

Registry Design Captures Signal, Not Microbiology

The study used an SRTR-derived binary infection indicator recorded during follow-up. It did not separate bacterial, viral, fungal, or opportunistic infection, and it did not provide microbiologic etiology or infection timing. Those constraints matter because a single infection flag can compress very different clinical events into one outcome. A bloodstream infection, cytomegalovirus disease, and fungal pneumonia do not carry the same biology, treatment intensity, or prognostic weight.

The investigators also excluded records with indeterminate infection status or invalid or unavailable medication information, and they did not apply multiple-comparison correction. Each drug-specific model contained one exposure indicator, and baseline characteristics were assessed in separate univariable models rather than used as adjustment covariates. As a result, the analysis is best read as hypothesis-generating registry epidemiology rather than causal proof.

What the Findings Can and Cannot Tell Transplant Teams

The practical value of the study lies in its scale and organ-specific granularity. By comparing several transplant cohorts side by side, it shows how infection risk and survival associations differ across liver, kidney, heart, lung, pancreas, heart-lung, and pancreas-kidney transplantation. It also argues against any simplistic assumption that one immunosuppressant has the same infectious profile in every recipient.

Still, the dataset cannot answer whether a given drug caused the infection signal, whether centers selected certain agents for patients already at higher risk, or whether infection timing preceded later survival differences. The registry does not provide the full time-stamped clinical trajectory needed to sort those questions out. Future work will need causal-inference approaches and granular clinical timelines to distinguish drug effect from confounding by indication, transplant severity, and postoperative complications.

Even with those limits, one point is hard to ignore: postoperative infection in solid organ transplantation is not a secondary endpoint. It tracks with lower survival, and the drugs used to suppress rejection do not behave identically across organs. Any regimen choice that ignores that organ-specific biology is likely to oversimplify the risk that transplant recipients actually face.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by Frontiers in Immunology.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA